The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Modern Pediatric Hodgkin Lymphoma: Response-Adapted Therapy with Brentuximab and Checkpoint Inhibitors

Contemporary risk-stratified treatment approach for pediatric and adolescent Hodgkin lymphoma optimizing cure rates while minimizing late toxicity through response-adapted protocols

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Modern Pediatric Hodgkin Lymphoma: Response-Adapted Therapy with Brentuximab and Checkpoint Inhibitors?

Pediatric Hodgkin lymphoma is B-cell lymphoma with characteristic Reed-Sternberg cells representing approximately 7% of childhood cancers.

Classical Hodgkin lymphoma subtypes include nodular sclerosis, mixed cellularity, lymphocyte-rich and lymphocyte-depleted with stage-stratified prognosis.

Risk stratification incorporates stage, B symptoms, bulky disease, extranodal involvement and early response to induction chemotherapy.

Response-adapted protocols use interim PET-CT after 2 cycles to escalate therapy in poor responders or de-escalate in early responders.

Modern multi-institutional cooperative group protocols continually refine risk stratification and response criteria optimizing outcomes.

Symptoms

Painless cervical or supraclavicular lymphadenopathy is most common presentation with persistent enlargement over weeks.
B symptoms including fever, drenching night sweats, weight loss greater than 10% indicate adverse prognosis.
Mediastinal mass causing cough, chest pain or superior vena cava obstruction may present in advanced disease.
Pruritus, alcohol-induced lymph node pain represent characteristic but uncommon presentations.
Extranodal involvement including spleen, liver, bone marrow, lung in stage IV disease affects treatment intensity.

Risk Factors

Adolescent and young adult age peak with bimodal incidence pattern in pediatric oncology.
Epstein-Barr virus association with mixed cellularity subtype and developing world predominance.
Family history with concordance in monozygotic twins suggests genetic susceptibility component.
Immunodeficiency including HIV, post-transplant immunosuppression increases lymphoma risk.
Higher socioeconomic status, smaller family size and delayed EBV exposure correlate with classical Hodgkin in industrialized countries.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent painless lymphadenopathy especially cervical or supraclavicular in adolescent warrants oncologic evaluation with biopsy.
  • Mediastinal mass on chest imaging with bulky disease requires expedited multidisciplinary tertiary referral.
  • B symptoms including unexplained fever, night sweats, weight loss in adolescent suggest possible lymphoma.
  • Family history of Hodgkin lymphoma or known genetic susceptibility warrants heightened surveillance and early evaluation.
  • Pediatric oncology center with cooperative group protocol enrollment optimizes outcomes through standardized contemporary therapy.

Treatment Methods

01
Frontline regimens include ABVE-PC, OEPA-COPDAC and brentuximab-AVD with stage-stratified intensity.
02
Interim PET-CT after 2 cycles guides response-adapted therapy escalation or de-escalation.
03
Brentuximab vedotin anti-CD30 antibody-drug conjugate incorporation in high-risk disease improves event-free survival.
04
Reduced involved-site radiation therapy in PET-negative early responders minimizes late effects.
05
Comprehensive survivorship care including late effects screening, cardiac surveillance, secondary malignancy monitoring, fertility counseling, psychosocial support optimizes long-term outcomes for this highly curable pediatric malignancy.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.